You are here: Industry Insights > Pfizer

News List

Bayer to stop Essure sales at year-end biospectrumasia
July 24, 2018
The birth control treatment is alleged to have harmed thousands of women in the past two decades.
Biogen buys Pfizer’s schizophrenia drug pharmatimes
July 24, 2018
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
Pfizer bags approval for Neupogen biosimilar pharmatimes
July 24, 2018
Pfizer’s Neupogen biosimilar Nivestym has been approved by the US Food and Drug Administration and is expected to hit the market at a “significant discount” to its reference drug.
GSK no longer vying for Pfizer’s consumer assets pharmatimes
July 20, 2018
GlaxoSmithKline has revealed that it will not bid for Pfizer’s consumer healthcare business, pulling out of the process just days after rival suitor Reckit Benckiser stepped away from a potential deal.
Winning Trump’s praise was easy for Pfizer. Wall Street and the Hill? Not so much fiercepharma
July 18, 2018
When President Donald Trump praised Pfizer on Twitter for delaying price hikes on 40 of its drugs last week
Pfizer halts production at India injectables plant after FDA again finds issues fiercepharma
July 18, 2018
Pfizer has again suspended production at a long-troubled sterile injectables plant in India that the FDA has twice before cited for manufacturing and testing issues.
Pfizer, Allogene link to develop cancer therapies pharmatimes
July 18, 2018
Pfizer and Allogene have entered into an agreement to develop allogeneic CAR T cell therapies.
Pfizer files lung cancer drug in the EU, US pharmatimes
July 18, 2018
Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.
With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost fiercepharma
July 17, 2018
Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread through the body.
Trump slams Pfizer over price hikes, Pfizer responds pharmafile
July 17, 2018
Price hiking in the pharmaceutical industry continues to persist, and has become ever more prominent in the public sphere thanks to in part to Donald Trump’s sporadic highlighting of the issue leading up to and throughout his presidency.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page